Pletal (Cilostazol) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 13, 2015 Category: Drugs & Pharmacology Source Type: news
Two Antiplatelet Add-on Regimens About Equal (CME/CE)
(MedPage Today) -- Adding cilostazol (Pletal) to standard dual antiplatelet therapy performed as well as doubling the dose of clopidogrel (Plavix) after implantation of a drug-eluting stent, the HOST-ASSURE study showed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 17, 2013 Category: Cardiology Source Type: news
EMA recommends restricting cilostazol use for PAD
The Europeans Medicines Agency has recommended restricting the use of cilostazol in patients with intermittent claudication. Use should be avoided in those with cardiac problems or on dual anticoagulants. (Source: theHeart.org)
Source: theHeart.org - March 22, 2013 Category: Cardiology Source Type: news
EMA Recommends Restricting Cilostazol Use for PADEMA Recommends Restricting Cilostazol Use for PAD
The Europeans Medicines Agency has recommended restricting the use of cilostazol in patients with intermittent claudication. Use should be avoided in those with cardiac problems or on dual anticoagulants News Alerts (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 22, 2013 Category: Cardiology Tags: Diabetes & Endocrinology News Alert Source Type: news
EU medicines agency to restrict use of Otsuka drug
LONDON (Reuters) - The European Medicines Agency said on Friday it was recommending restricting the use of medicines containing cilostazol, sold by Otsuka under the brand name Pletal, following concerns over side effects. (Source: Reuters: Health)
Source: Reuters: Health - March 22, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
European Medicines Agency recommends restricting use of cilostazol-containing medicines
Source: EMA
Area: News
Following a review of the current evidence, the European Medicines Agency's (EMA) Committee on Medicinal Products for Human Use (CHMP) has recommended that the use of cilostazol in the treatment of intermittent claudication should be restricted with a range of new measures aimed at targeting a patient population in which there are clinical benefits, and at the same time minimising important risks.
The Spanish Agency for Medicines and Health Products (AEMPS) asked the CHMP to carry out a review of cilostazol following a number of reports of serious suspected adverse effects, in particular...
Source: NeLM - Cardiovascular Medicine - March 22, 2013 Category: Cardiology Source Type: news
